Zealand Pharma A/S (ZLDPF) Projected to Post Quarterly Earnings on Thursday

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) is expected to be releasing its earnings data on Thursday, May 15th. Analysts expect Zealand Pharma A/S to post earnings of ($0.77) per share and revenue of $248.61 million for the quarter.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.19. The firm had revenue of $1.30 million during the quarter, compared to analysts' expectations of $28.11 million. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. On average, analysts expect Zealand Pharma A/S to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Zealand Pharma A/S Stock Down 5.0 %

Shares of ZLDPF opened at $70.57 on Thursday. The company has a quick ratio of 35.49, a current ratio of 35.49 and a debt-to-equity ratio of 0.03. The business has a fifty day moving average of $72.44 and a 200 day moving average of $94.25. The company has a market cap of $5.01 billion, a PE ratio of -29.90 and a beta of 0.92. Zealand Pharma A/S has a 52-week low of $57.97 and a 52-week high of $141.74.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ZLDPF. William Blair upgraded shares of Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a report on Friday, March 7th. Cantor Fitzgerald upgraded Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, January 21st.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.